0.05 mg/kg, DLI – 24 hours, dose of light – 40 J/cm2

Slides:



Advertisements
Similar presentations
Carcinogen - an agent known to cause cancer.
Advertisements

Content Standard 1.2 Cells can differentiate and may develop into complex multicellular organisms (i.e., cells, tissues, organs, organ systems, organisms).
Basal Cell Nevus Syndrome Daniel Berg M.D., FRCPC Director, Dermatologic Surgery University of Washington.
Skin Cancer A few questions A few photos A few suggestions Dr Peter Allen.
Skin Cancers. Actinic Keratosis Chronic sun exposure is the cause of almost all actinic keratoses. Sun damage to the skin is cumulative, so even a brief.
NonMelanoma Skin Cancer Dr David Burdon-Jones Consultant Dermatologist Dorset County Hospital Foundation Trust Interactive.
Non-Melanoma Skin Cancer Treated with Electronic Brachytherapy: Results at Two Years Ajay Bhatnagar MD, MBA Cancer Treatment Services Arizona Casa Grande,
Soft Tissue Surgery Scott M. Strayer, MD, MPH Assistant Professor University of Virginia Health System Department of Family Medicine.
National Specialist Dermatopathology EQA Scheme Circulation A.
Basal Cell Carcinoma Presented by: Bill V. Way, D.O. AOCD Board Certified Dermatologist Residency in US Army at Walter Reed Consultant for Charlton Methodist.
By Tord Høgsand and Magnus Sundstrøm
This slide shows a tumor metastasizing, or breaking up and traveling to different parts of the body.
Case Study 63: Cancer of the Female Breast
A phase I study on the combination of neoadjuvant radiotherapy plus pazopanib in patients with locally advanced soft tissue sarcoma of the extremities.
Presented by Robert S. Stern, M.D. at the September 10, 2003 meeting of the Dermatologic and Ophthalmic Drugs Advisory Committee.
Cutaneous Malignancies
Burns Burns are categorized by severity as first, second, or third degree. First degree burns are similar to a painful sunburn, causing redness and swelling.
بسم الله الرحمن الرحيم Sudan University of Science and Technology College of Postgraduate Studies Evaluation of the Efficacy of Carbon Dioxide Laser in.
Recurrent Respiratory Papillomatosis (RRP): Basic Science to Clinical Studies Mark J. Shikowitz, MD Bettie M. Steinberg, PhD Long Island Jewish Medical.
Squamous Cell Carcinoma Danielle Gentry 2 nd Hour.
ICNCT-16, , Helsinki, Finland
Photodynamic Therapy for breast cancer
Clinical results of BNCT for Head and Neck melanoma J. Hiratsuka, N.Kamitani, N.Morita T.Aihara, A.Maruhashi * and K.Ono * Kawasaki Medical School *Research.
T. Aihara 1, 2, N. Morita 2, N. Kamitani 3, H. Kumada 1, K. Oonishi 1, M. Suzuki 4, J. Hiratsuka 3, H. Sakurai 1. 1 Proton Medical Research Centre, University.
Photodynamic Therapy Dosimetry
Drugs in the Body (1) Recurrence Relations A patient is given an initial dose of 50mg of a drug. Each hour the patient is given a 20mg tablet of the.
External Ear Basosquamous cell carcinoma 1 Instructor: 杜宗陽主任 Reporter: 張廷碩.
Skin Care and Issues. Asymmetry Symmetrical Asymmetrical.
Basal Cell Cancer: Update on Treatment and Management.
Display 4-1: Therapies that Disqualified Patients as Responders  Phototherapy (PUVA, UVB)  Systemic retinoids  High potency topical corticosteroids.
Behcet's Disease in an Indian Patient
CRYOSURGERY Pattippa Sumalai, M.D. Jutamas Tankunakorn, M.D. 23/09/2014.
Photodynamic Therapy for Pre-cancerous lesions of the skin Alan Milligan Clinical Nurse Specialist for Non-Melanoma Skin Cancers.
Salvage Nipple-Sparing Mastectomy and Immediate Breast Reconstruction after Previous Breast Conservation Therapy: Same Safety, Better Cosmesis Che-Hsiung.
Breast Surgery in Delhi Breast Cancer Epidemiology Halsted Theory Radical Mastectomy Fisher Theory Modified Radical Mastectomy Goals of Breast Conservation.
ESMO 2016 Durvalumab Data Study / Abstract Ph Indication Line N Arms
“Malignant skin tumors”
Treatment of pseudofolliculitis barbae in skin types IV, V, and VI with a long-pulsed neodymium:yttrium aluminum garnet laser  E.Victor Ross, MD, Linda.
Non-melanoma skin cancer reconstruction of the head and neck region at Northampton General Hospital: a case series. Iqbal U1, Kapasi F2 Ameerally P3 1.
Bronchoscopy-Guided Cooled Radiofrequency Ablation as a Novel Intervention Therapy for Peripheral Lung Cancer Respiration 2015;90: DOI: /
Results of Definitive Radiotherapy in Anal Canal Carcinoma
Case Study: BKA Buerger’s Disease
Female patient I. 52 years old trophic ulcer of the left lower leg associated with chronic venous insufficiency, duration of the disease is more than 2,5.
Daniel Keith – Dermatology Registrar
Optical coherence tomography imaging of non-melanoma skin cancer undergoing photodynamic therapy reveals subclinical residual lesions  L. Themstrup, C.A.
European Research on Electrochemotherapy in Head and Neck Cancer (EURECA) project: Results of the treatment of skin cancer  Giulia Bertino, Gregor Sersa,
Skin Cancer A Colorado Concern.
Acne Scars B&A Pictures
Bevacizumab in platinum-sensitive ovarian cancer: OCEANS.
Mary Collier, FCSE, MS Texas AgriLIFE Extension Service, Terry County
Activity Goals Incidence of Basal Cell Carcinoma (BCC)
Successful Osimertinib Rechallenge in a Patient with T790M-Mutant Non–Small Cell Lung Cancer after Osimertinib-Induced Interstitial Lung Disease  Eisaku.
Basal Cell Carcinoma.
Rossi A et al. Proc ASCO 2011;Abstract 8008.
Palumbo A et al. Proc ASCO 2011;Abstract 8007.
Shoulder edge anterior adduction contracture in pediatric patients after burns: Anatomy and treatment: A new approach  Viktor M. Grishkevich, Max Grishkevich,
Sarcoma Wound Complications
NURSING CARE MANAGEMENT OF BURNS IN ER
Understanding How to Document Lacerations
The 12-month analysis from Basal Cell Carcinoma Outcomes with LDE225 Treatment (BOLT): A phase II, randomized, double-blind study of sonidegib in patients.
Clinical responses in patients.
Prolonged Activation of ERK Contributes to the Photorejuvenation Effect in Photodynamic Therapy in Human Dermal Fibroblasts  Yong Hyun Jang, Gi-Bang Koo,
Supplemental Fig. 1 Fig. S1. Requirement for both ALA treatment and irradiation to elicit a stress response. PC3 cells in serum-free medium were dark-incubated.
NSG mice transplanted with human primary ALK-positive ALCL tumor grafts were administered either doxorubicin, 10 mg/kg i.v. or CEP orally, 100 mg/kg,
The treatment history and genomic landscape of a metastatic carcinoma with an extreme outlier response to combination therapy. The treatment history and.
Use of a hydrocolloid dressing to aid in the closure of surgical wounds in patients with fragile skin  Jason D. Mazzurco, DO, MS, Kent Jerome Krach, MD 
Fig. 2. Illustrative case. A 22-year-old male patient presented with visual field defects. A: Initial MRI showed pituitary adenoma. B: Suspicious residual.
GCS-100 selectively kills KRAS-addicted lung tumors.
Presentation transcript:

0.05 mg/kg, DLI – 24 hours, dose of light – 40 J/cm2 Patient L. 83 years old, male. Before treatment Recurrent basal-cell skin cancer of the face. Tumor diameter: 10 mm Day 5 after PDT. Hemorrhages and mild edema of the tumor. Day 12 after PDT. Complete tumor necrosis. Beginning border epithelization. PDT result Recurrence-free period – 12 months

0.05 mg/kg, DLI – 24 hours, dose of light – 50 J/cm2 Patient S. 86 years old, male. Before treatment Multiple BCC and SCC of the face and head. 24 tumors, maximal diameter – 35 mm, thickness of 4 tumors – over 3 mm. Day 13 after PDT. Complete necrosis of all tumors. Due to close placement of the tumors, some irradiation fields overlapped, and the dose of light was doubled.. PDT result CR, excellent cosmetic result. Recurrence-free period – 4 months

0.05 mg/kg, DLI – 24 hours, dose of light – 40 J/cm2 Patient L. 83 years old, male. Before treatment Large recurrence of basal-cell skin cancer of the nose and periorbital area. Seven recurrent tumors on the border of the scar after cryosurgery, maximal diameter – 10 mm. Day 5 after PDT. Complete tumor necrosis. Day 12 after PDT. Epithelization of skin defect under the crust PDT result Recurrence-free period – 10 months

0.05 mg/kg, DLI – 24 hours, dose of light – 50 J/cm2 Patient B. 65 years old, male. Before treatment Large recurrent basal-cell skin cancer of the face. Tumor diameter – 35 mm, tumor thickness – 6 mm. Day 5 after PDT. Complete tumor necrosis. PDT result Recurrence-free period – 4 months

Foscan dose – 0.05 mg/kg drug-light interval – 48 hours

0.05 mg/kg, DLI – 48 hours, dose of light – 40 J/cm2 Patient F. 75 years old, male. Before treatment Primary basal-cell skin cancer of the nose. Tumor size: 12x7 mm, tumor thickness: over 3 mm. PDT result Recurrence-free period – 10 months

0.05 mg/kg, DLI – 48 hours, dose of light – 50 J/cm2 Patient K. 75 years old, female. Before treatment Primary basal-cell skin cancer of the nose. Tumor diameter – 12 mm, tumor thickness: over 3 mm. Day 5 after PDT Complete necrosis of the tumor PDT result Recurrence-free period – 7 months

0.05 mg/kg, DLI – 48 hours, dose of light – 50 J/cm2 Patient S. 61 years old, male. Before treatment Recurrent basal-cell skin cancer of the auricle. Tumor dimensions – 30x25mm. PDT result Recurrence-free period – 4 months

0.05 mg/kg, DLI – 48 hours, dose of light – 100 J/cm2 Patient S. 87 years old, male. Before treatment Solid primary basal-cell skin cancer of the head. Tumor diameter: 17 mm, Tumor thickness: 4 mm. 2 days after PDT. Complete tumor necrosis. 34 days after PDT. Partial wound healing. PDT result CR, good cosmetic result. Recurrence-free period – 6 months

0.05 mg/kg, DLI – 48 hours, dose of light – 100 J/cm2 Patient C. 56 years old, male. Before treatment Primary basal-cell skin cancer of periorbital area. Interfluent tumors occupy total area 20x12 mm, tumor thickness: over 3 mm. PDT result Recurrence-free period – 4 months

Foscan dose – 0.04 mg/kg drug-light interval – 24 hours

0.04 mg/kg, DLI – 24 hours, dose of light – 40 J/cm2 Patient B. 68 years old, male. Before treatment Multiple basal-cell skin cancer of the head, chest, back, arms. A total of 23 tumors, maximum tumor size: 25 mm, thickness of 4 tumors exceeded 3 mm. Day 13 after PDT. Complete necrosis of all tumors. PDT result Recurrence-free period – 7 months

0.04 mg/kg, DLI – 24 hours, dose of light – 50 J/cm2 Patient R. 75 years old, female. Before treatment Primary basal-cell skin cancer of periorbital area. Tumor diameter – 7 mm. PDT result Recurrence-free period – 7 months

0.04 mg/kg, DLI – 24 hours, dose of light – 60 J/cm2 Patient S. 78 years old, male. Before treatment Primary basal-cell skin cancer of periorbital area. Tumor diameter – 15 mm. PDT result Recurrence-free period – 7 months

0.04 mg/kg, DLI – 24 hours, dose of light – 100 J/cm2 Patient M. 68 years old, female. Day 8 after PDT. Complete tumor necrosis. PDT result Recurrence-free period – 8 months Before treatment Recurrent basal-cell skin cancer of left periorbital area. Multiple tumors, maximum diameter: 10 mm.

Foscan dose – 0.03 mg/kg drug-light interval – 24 hours

0.03 mg/kg, DLI – 24 hours, dose of light – 80 J/cm2 Patient M. 69 years old, male. Day 7 after PDT. Hemorrhagic necrosis. Before treatment Recurrent basal-cell skin cancer of left retroauricularis area. Tumor size: 18 mm. PDT result Recurrence-free period – 8 months